【Brief News】Shenzhen Cell Valley Invited to Attend the 2023 IVB Shenzhen Gene Therapy & Nucleic Acid Drug Summit

Date:11-29  Hits:  Belong to:News

图片.png

On November 24, Shenzhen Cell Valley was invited to attend the 2023 IVB Shenzhen Gene and Cell Therapy & Nucleic Acid Drug Summit, themed "Biotechnology Gives New Life," hosted by Shanghai Bomaishi Medical Services Co., Ltd., the Cell Medicine Branch of the China Food and Drug Corporation Quality and Safety Promotion Association, and the Vaccine and Biological Products Quality uation and Standards Professional Committee. The summit centered on revolutionary breakthroughs in innovative drugs such as gene and cell therapies, bringing together industry leaders, experts, and innovators to explore the potential of genetic medicine and give patients new opportunities for life.

图片.png

Dr. Zhao Lijun, Head of R&D at our company, attended and delivered a keynote speech titled "Current Status and Prospects of Cell Therapy," providing an in-depth introduction to the development background, current status, and future trends of cell therapy, with a focus on the advantages of Shenzhen Cell Valley's core technology—industrial-grade retroviral vector technology (PackRV-SS). As an enterprise in the frontier innovative biotechnology field of cell and gene therapy, Shenzhen Cell Valley focuses on addressing bottlenecks in large-scale industrial production in the cell and gene therapy field. Through active participation in domestic and international exchange and cooperation, it has established strategic partnerships with leading domestic enterprises, medical institutions, research organizations, and universities, jointly advancing the R&D, clinical practice, and application of cell therapy drugs, supporting the translation of research achievements, and benefiting more patients.


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@sz-cell.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Cell Valley Group is a leading CGT infrastructure platform in China. We capitalize on the strategic window opened by Decree No. 818 to bridge the gap between clinical research and commercialization.

We pioneer the "Hospital to Industry" (H2I) model. Basically, we act as the core partner for hospitals, providing a one-stop solution for new biomedical tech—covering process development, GMP manufacturing, QC, and commercial rollout. Our mission is to push China's CGT sector from pure R&D into a standardized, scalable industry.